Please Wait.....
Report
Dementia Drugs Market By Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), By Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-10-01 I 265 Pages I Allied Market Research
The global dementia drugs market accounted for $8662.17 million in 2021, and is expected to reach $19704.27 million by 2031, registering a CAGR of 8.5% from 2022 to 2031.
Dementia is a syndrome in which there is deterioration in thinking, behavior, memory, and ability to perform daily activities. The most common form of dementia is Alzheimer disease. Dementia results from many injuries and disease that primarily or secondarily impact the brain. There is often lack of awareness about dementia, which results in obstacles to examination and care. Cholinesterase Inhibitors are most commonly prescribed medicines, which help prevent break down of acetylcholine in the brain as acetylcholine is essential in learning, memory, and mood of individual.
It is estimated that the dementia drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Alzheimer's disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, the growing geriatric population, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine, further facilitate the growth of the market. However, strict government regulation related to product approval and high cost linked to R&D activity are expected to impede the market growth. In contrast, accelerated technological advancement in drug discovery technique and high investment by the government for drug development are factors that present new pathway in the industry, which are anticipated to provide significant growth opportunities for the dementia drugs market.
The dementia drugs market is segmented on the basis of indication, drug class, distribution channel, and region. On the basis of indication, the market is bifurcated into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and other indications. Depending on drug class, the market is classified into cholinesterase inhibitors and NMDA antagonist and its combination drugs. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global dementia dugs market. The key companies profiled in the report include AbbVie Inc., APPOTEX Inc., Aurobindo Pharma Limited, Biogen Idec Inc., EISAI GLOBAL, Eli Lilly and company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG and Teva Pharmaceuticals
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dementia drugs market analysis from 2021 to 2031 to identify the prevailing dementia drugs market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the dementia drugs market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global dementia drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Indication
- Lewy Body Dementia
- Parkinsons Disease Dementia
- Alzheimers Disease
- Vascular Dementia
- Other Indications
By Drug Class
- Cholinesterase Inhibitors
- NMDA Antagonists and its Combination Drugs
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- apotex inc.
- Aurobindo Pharma Ltd
- Biogen Idec
- Eisai
- Eli Lilly and Company
- Johnson & Johnson
- Abbvie Inc
- , F. Hoffmann-La Roche AG
- Teva Pharmaceutical Industries
- Novartis AG
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: DEMENTIA DRUGS MARKET, BY INDICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Lewy Body Dementia
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Parkinsons Disease Dementia
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Alzheimers Disease
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5 Vascular Dementia
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country
4.6 Other Indications
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market share analysis by country
CHAPTER 5: DEMENTIA DRUGS MARKET, BY DRUG CLASS
5.1 Overview
5.1.1 Market size and forecast
5.2 Cholinesterase Inhibitors
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 NMDA Antagonists and its Combination Drugs
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Retail Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Hospital Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: DEMENTIA DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Indication
7.2.3 North America Market size and forecast, by Drug Class
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Indication
7.2.5.1.3 Market size and forecast, by Drug Class
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Indication
7.2.5.2.3 Market size and forecast, by Drug Class
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Indication
7.2.5.3.3 Market size and forecast, by Drug Class
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Indication
7.3.3 Europe Market size and forecast, by Drug Class
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Indication
7.3.5.1.3 Market size and forecast, by Drug Class
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Indication
7.3.5.2.3 Market size and forecast, by Drug Class
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Indication
7.3.5.3.3 Market size and forecast, by Drug Class
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Indication
7.3.5.4.3 Market size and forecast, by Drug Class
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Indication
7.3.5.5.3 Market size and forecast, by Drug Class
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Indication
7.3.5.6.3 Market size and forecast, by Drug Class
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Indication
7.4.3 Asia-Pacific Market size and forecast, by Drug Class
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Indication
7.4.5.1.3 Market size and forecast, by Drug Class
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 Japan
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Indication
7.4.5.2.3 Market size and forecast, by Drug Class
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Indication
7.4.5.3.3 Market size and forecast, by Drug Class
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 South Korea
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Indication
7.4.5.4.3 Market size and forecast, by Drug Class
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 Australia
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Indication
7.4.5.5.3 Market size and forecast, by Drug Class
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Indication
7.4.5.6.3 Market size and forecast, by Drug Class
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Indication
7.5.3 LAMEA Market size and forecast, by Drug Class
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Indication
7.5.5.1.3 Market size and forecast, by Drug Class
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Indication
7.5.5.2.3 Market size and forecast, by Drug Class
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Indication
7.5.5.3.3 Market size and forecast, by Drug Class
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Indication
7.5.5.4.3 Market size and forecast, by Drug Class
7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 apotex inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Aurobindo Pharma Ltd
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Biogen Idec
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eisai
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Johnson & Johnson
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Abbvie Inc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 , F. Hoffmann-La Roche AG
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Teva Pharmaceutical Industries
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Novartis AG
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 2. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 8. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 10. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 13. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. GLOBAL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 18. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 24. DEMENTIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 27. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. NORTH AMERICA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 30. U.S. DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 31. U.S. DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. CANADA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 34. CANADA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 36. MEXICO DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 37. MEXICO DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. EUROPE DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 44. GERMANY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. FRANCE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 46. FRANCE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. UK DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 49. UK DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 50. UK DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ITALY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ITALY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 53. ITALY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 56. SPAIN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. REST OF EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 59. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 62. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. CHINA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 65. CHINA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 66. CHINA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. JAPAN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 68. JAPAN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 69. JAPAN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. INDIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 71. INDIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 72. INDIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. SOUTH KOREA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 74. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 75. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. AUSTRALIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 77. AUSTRALIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 78. AUSTRALIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 80. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 81. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 82. LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 83. LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 84. LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. LAMEA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 86. BRAZIL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 87. BRAZIL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 88. BRAZIL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 92. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 93. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 94. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 95. REST OF LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 96. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 97. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 98.APOTEX INC.: COMPANY SNAPSHOT
TABLE 99.APOTEX INC.: OPERATING SEGMENTS
TABLE 100.APOTEX INC.: PRODUCT PORTFOLIO
TABLE 101.APOTEX INC.: NET SALES
TABLE 102.APOTEX INC.: KEY STRATERGIES
TABLE 103.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
TABLE 104.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
TABLE 105.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
TABLE 106.AUROBINDO PHARMA LTD: NET SALES
TABLE 107.AUROBINDO PHARMA LTD: KEY STRATERGIES
TABLE 108.BIOGEN IDEC: COMPANY SNAPSHOT
TABLE 109.BIOGEN IDEC: OPERATING SEGMENTS
TABLE 110.BIOGEN IDEC: PRODUCT PORTFOLIO
TABLE 111.BIOGEN IDEC: NET SALES
TABLE 112.BIOGEN IDEC: KEY STRATERGIES
TABLE 113.EISAI: COMPANY SNAPSHOT
TABLE 114.EISAI: OPERATING SEGMENTS
TABLE 115.EISAI: PRODUCT PORTFOLIO
TABLE 116.EISAI: NET SALES
TABLE 117.EISAI: KEY STRATERGIES
TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 121.ELI LILLY AND COMPANY: NET SALES
TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 123.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 124.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 125.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 126.JOHNSON & JOHNSON: NET SALES
TABLE 127.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 128.ABBVIE INC: COMPANY SNAPSHOT
TABLE 129.ABBVIE INC: OPERATING SEGMENTS
TABLE 130.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 131.ABBVIE INC: NET SALES
TABLE 132.ABBVIE INC: KEY STRATERGIES
TABLE 133., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 134., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 135., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 136., F. HOFFMANN-LA ROCHE AG: NET SALES
TABLE 137., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 138.TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 139.TEVA PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS
TABLE 140.TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 141.TEVA PHARMACEUTICAL INDUSTRIES: NET SALES
TABLE 142.TEVA PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES
TABLE 143.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 144.NOVARTIS AG: OPERATING SEGMENTS
TABLE 145.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 146.NOVARTIS AG: NET SALES
TABLE 147.NOVARTIS AG: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.DEMENTIA DRUGS MARKET SEGMENTATION
FIGURE 2.DEMENTIA DRUGS MARKET,2021-2031
FIGURE 3.DEMENTIA DRUGS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.DEMENTIA DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.DEMENTIA DRUGS MARKET,BY INDICATION,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF LEWY BODY DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PARKINSONS DISEASE DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ALZHEIMERS DISEASE DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF VASCULAR DEMENTIA DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER INDICATIONS DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 18.DEMENTIA DRUGS MARKET,BY DRUG CLASS,2021(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHOLINESTERASE INHIBITORS DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF NMDA ANTAGONISTS AND ITS COMBINATION DRUGS DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 21.DEMENTIA DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES DEMENTIA DRUGS MARKET,2021-2031(%)
FIGURE 25.DEMENTIA DRUGS MARKET BY REGION,2021
FIGURE 26.U.S. DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 27.CANADA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 28.MEXICO DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 29.GERMANY DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 30.FRANCE DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 31.UK DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 32.ITALY DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 33.SPAIN DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 34.REST OF EUROPE DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 35.CHINA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 36.JAPAN DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 37.INDIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 38.SOUTH KOREA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 39.AUSTRALIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 40.REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 41.BRAZIL DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 42.SAUDI ARABIA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 43.SOUTH AFRICA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 44.REST OF LAMEA DEMENTIA DRUGS MARKET,2021-2031($MILLION)
FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 49.COMPETITIVE DASHBOARD
FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 51.APOTEX INC..: NET SALES ($MILLION)
FIGURE 52.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)
FIGURE 53.BIOGEN IDEC.: NET SALES ($MILLION)
FIGURE 54.EISAI.: NET SALES ($MILLION)
FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
FIGURE 56.JOHNSON & JOHNSON.: NET SALES ($MILLION)
FIGURE 57.ABBVIE INC.: NET SALES ($MILLION)
FIGURE 58., F. HOFFMANN-LA ROCHE AG.: NET SALES ($MILLION)
FIGURE 59.TEVA PHARMACEUTICAL INDUSTRIES.: NET SALES ($MILLION)
FIGURE 60.NOVARTIS AG.: NET SALES ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security